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Abstract
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in
hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/
refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received
moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days for ≤6 cycles. Blinded independent
central review determined disease response and minimal residual disease (MRD) status. Among 80 patients (79% males;
median age, 60.0 years), durable complete response (CR) rate was 30%, CR rate was 41%, and objective response rate (CR
and partial response) was 75%; 64 patients (80%) achieved hematologic remission. Among complete responders, 27 (85%)
achieved MRD negativity by immunohistochemistry. The most frequent adverse events (AEs) were peripheral edema (39%),
nausea (35%), fatigue (34%), and headache (33%). Treatment-related serious AEs of hemolytic uremic syndrome (7.5%) and
capillary leak syndrome (5%) were reversible and generally manageable with supportive care and treatment discontinuation
(6 patients; 7.5%). Moxetumomab pasudotox treatment achieved a high rate of independently assessed durable response and
MRD eradication in heavily pretreated patients with HCL, with acceptable tolerability.
Introduction
Patients with hairy cell leukemia (HCL), a rare B cell
malignancy characterized by high CD22 expression, typi-
cally present with pancytopenia and increased susceptibility
to infection [1]. Although many patients achieve long-term
complete remission with the purine nucleoside analogs
pentostatin or cladribine [2–4], ~50% will relapse by 16
years and require additional treatment [5]. In later lines,
purine nucleoside analogs offer lower complete response
rate, shorter duration of response, and higher risk of
cumulative toxicity compared with earlier treatment [5–7].
Of note, purine nucleoside analogs are associated with
severe infection due to profound neutropenia [8].
Targeted therapies, such as vemurafenib, ibrutinib, and
rituximab, show encouraging efﬁcacy but rarely
eradicate minimal residual disease in patients with
complete response as single agents, and are often associated
with safety and tolerability concerns [5, 9–18]. An unmet
need remains in relapsed/refractory HCL for therapies
that provide durable complete response with eradication
of minimal residual disease and less myelo/
immunosuppression.
Moxetumomab pasudotox (CAT-8015) is a recombinant
immunotoxin targeting CD22, composed of an immu-
noglobulin light chain variable domain and a heavy chain
variable domain genetically fused to a truncated form of
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Pseudomonas exotoxin PE38 [19]. In a phase 1 study of
patients with relapsed/refractory HCL, 49 patients received
moxetumomab pasudotox [20]. The objective response rate
was 86%, with a complete response rate of 57%; 63% of
patients who achieved complete response were minimal
residual disease negative by immunohistochemistry as
assessed by an independent central reviewer, and similar
percentage by ﬂow cytometry, either of which translated
into longer duration of complete response and/or
progression-free survival [20, 21]. The current study eval-
uated the rate of durable complete response with mox-
etumomab pasudotox in patients with multiply relapsed
HCL.
Methods
Study design and organization
This pivotal, multicenter, single-arm open-label study
(clinicaltrials.gov identiﬁer: NCT01829711) was conducted
at 32 centers in 14 countries. The study was performed in
accordance with the principles of the Declaration of Hel-
sinki, the International Conference on Harmonisation/Good
Clinical Practice guidelines, and applicable regulatory
requirements. The protocol was approved by the institu-
tional review board at each center. All patients provided
written informed consent.
The authors designed the study in collaboration with the
sponsor. Data were collected and analyzed by the sponsor
and interpreted jointly with the authors. All authors had full
access to the data. The ﬁrst draft was written by the
authors and Peloton Advantage, who also provided
editorial support. All authors reviewed and contributed to
subsequent drafts and vouch for the completeness and
veracity of the data and analyses, and for adherence to the
protocol.
Patients
Adults with histologically conﬁrmed HCL and an indication
for treatment (deﬁned as at least one of the following:
neutrophils <1.0 × 109/L, platelets <100 × 109/L, hemoglo-
bin <10 g/dL, or symptomatic splenomegaly) were eligible.
Patients must have received at least two prior systemic
therapies, including two courses of a purine nucleoside
analog or one course of rituximab or a BRAF inhibitor
following a single prior purine nucleoside analog course.
An Eastern Cooperative Oncology Group performance
status of 0, 1, or 2 and adequate hepatic and renal function
were required. Detailed inclusion and exclusion criteria are
shown in the protocol.
Study treatment
Patients received moxetumomab pasudotox 40 μg/kg intra-
venously over 30 minutes on days 1, 3, and 5 of 28-day
cycles for a maximum of six cycles or until documentation
of minimal residual disease-negative complete response (as
assessed by the investigator), disease progression, initiation
of alternate therapy, or unacceptable toxicity. Patients
received prophylaxis for renal insufﬁciency (ﬂuids and low-
dose aspirin) and hypersensitivity reactions (hydroxyzine,
acetaminophen, and ranitidine; see protocol for details).
Study end points and assessments
The primary end point was durable complete response,
deﬁned as complete response assessed by blinded indepen-
dent central review with maintenance of hematologic remis-
sion for more than 180 days. Complete response was deﬁned
based on pathology (no evidence of hairy cells in bone
marrow by routine hemoxylin and eosin stain), imaging
(resolution of splenomegaly, hepatomegaly, and lymphade-
nopathy, documented by CT or MRI), and normalization of
hematologic parameters (neutrophils ≥1.5 × 109/L, platelets ≥
100 × 109/L, and hemoglobin ≥ 11.0 g/dL without growth
factors or transfusions in 4 weeks). Relapse was deﬁned as
loss of any criteria needed for best response, including
asymptomatic reappearance of hairy cells in the bone marrow
by hemoxylin and eosin stain. Additional details are described
in the protocol. Secondary efﬁcacy end points included
objective response rate, duration of complete and objective
response, progression-free survival, safety/tolerability,
immunogenicity, and pharmacokinetics.
Minimal residual disease was independently assessed
using immunohistochemistry. A blinded independent
pathologist assessed bone marrow biopsy specimens stained
for the HCL/B cell antigens CD20, CD79a, Annexin A1,
DBA.44, and PAX-5; additional details are in the Supple-
mentary Appendix. During treatment, minimal residual
disease was assessed locally at study sites by ﬂow cyto-
metric analysis of peripheral blood and/or bone marrow
aspirate, according to each site’s procedures.
Safety assessments included adverse events, serious
adverse events, and changes in clinical laboratory evalua-
tions and vital signs through 30 days after the last mox-
etumomab pasudotox dose. Adverse events and serious
adverse events were assessed by the investigators for rela-
tionship to moxetumomab pasudotox, graded using
National Cancer Institute Common Toxicity Criteria for
Adverse Events V4.03 and coded using Medical Dictionary
for Regulatory Activities V20.0.
Plasma moxetumomab pasudotox concentrations were
assessed at multiple time points following dosing.
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Pharmacokinetic parameters were estimated by non-
compartmental approach using Phoenix® WinNonlin®
(Version 6.3, Certara, Princeton, New Jersey). Immuno-
genicity was evaluated at multiple time points. Samples that
were positive for anti-drug antibodies were evaluated for
neutralization, speciﬁcity (PE38 versus CD22 binding
domain), and titer. Pharmacodynamics were assessed by
measuring peripheral blood B cell counts (CD19+ B cells
which include hairy cells) at multiple time points. Further
details are provided in the protocol.
Efﬁcacy was evaluated in the intent-to-treat population,
which included all patients who entered and received
moxetumomab pasudotox, and safety was evaluated in the
safety population, which comprised all patients who
received at least one dose of moxetumomab pasudotox;
both populations comprise the same 80 patients.
Statistical analysis
Rituximab was used as a historical control to determine
sample size, as it was the most frequently used non-
chemotherapy treatment in relapsed/refractory HCL with a
CR rate of 13% in the largest study [12, 22]. A sample size of
77 patients was planned to provide 90% power to detect a
difference between 13% and 28% in durable complete
response rates using a 2-sided signiﬁcance level of 0.05.
Durable complete response rate was constructed using the
exact probability method (Clopper–Pearson exact interval). If
the lower bound of the 95% CI was above 13% (or equiva-
lently, the binomial exact test one-sided p-value < 0.025), it is
concluded that the durable complete response rate was sig-
niﬁcantly higher than the historical control value of 13%.
Duration of complete response, duration of objective
response, and progression-free survival were estimated with
the use of the Kaplan–Meier method. In the analysis of
duration of complete response and objective response,
patients alive with no documented relapse prior to data cut-
off, dropout, or initiation of alternative anticancer therapy
were censored on the date of last disease assessment or
hematologic assessment, whichever occurred last. In the
analysis of progression-free survival, patients alive with no
documented relapse or disease progression prior to data cut-
off, dropout, or the initiation of alternative anticancer
therapy were censored on the date of last disease assessment
or hematologic assessment, whichever occurred last.
Role of funding source
This study and manuscript were funded by MedImmune,
the global biologics R&D arm of AstraZeneca. MedImmune
employees were involved in the study design, the collection,
analysis, and interpretation of data, the review of the
manuscript, and the decision to submit for publication.
Results
Patients
The database was locked on 24 May 2017. Eighty patients
were enrolled and treated (Table 1); 50 (62.5%) patients
completed six cycles of treatment and 12 (15.0%) dis-
continued early after achieving complete response with
negative minimal residual disease (Figure S1 in Supple-
mentary Appendix). Enrolled patients had received a med-
ian of three lines of prior therapy; 70 patients (87.5%)
received at least two lines of purine nucleotide analogs, 60
Table 1 Demographics and baseline characteristics
Characteristic Value (N= 80)
Age
Median, y 60.0
Range, y 34–84
Race (excluding patients enrolled in France [n= 8]
White, n (%) 70 (97.2)
Black, n (%) 1 (1.4)
Asian, n (%) 1 (1.4)
Ethnicity (excluding patients enrolled in France [n= 8]
Hispanic or Latino, n (%) 4 (5.6)
Not Hispanic or Latino, n no. (%) 67 (93.1)
Unknown, n no. (%) 1 (1.4)
Variant hairy cell leukemia—no. (%) 3 (3.8)
Splenectomy—no. (%) 5 (6.3)
Eastern Cooperative Oncology Group performance status—no. (%)
0 49 (61.3)
1 29 (36.3)
2 2 (2.5)
Extent of HCL
Median hemoglobin (range), g/dL 11.10 (6.5,
16.3)
Median neutrophil count (range), nL 0.81 (0.1, 6.2)
Median platelet count (range), nL 68 (6, 350)
Median hairy cell involvement in bone marrow,
% (range)a
85 (0, 100)
Median size of spleen, excluding splenectomy,
cm (range)
13.3 (8.9, 24.7)
Prior cancer therapy
Median number of lines of prior therapy (range) 3.0 (2, 11)
>3 prior lines, n (%) 39 (48.8)
Prior purine nucleoside analog, n (%) 80 (100)
Prior rituximab, n (%) 60 (75.0)
aDetermined by blinded independent pathologist read of hematoxylin
and eosin stained slides. Two patients were reported as not having
baseline bone marrow involvement. In one case there were technical
problems with the hematoxylin and eosin stained slides but 90%
involvement by immunohistochemistry; in the other case the patient
had variant HCL presenting as splenomegaly (182 mm)
1770 R. J. Kreitman et al.
Cycle 1
Day 1
Time
8
10
12
14
16
H
em
og
lo
bi
n 
(g
/d
L)
AllPD/NESDPRCR
Cycle 2
Day 1
Cycle 3
Day 1
Cycle 4
Day 1
Cycle 5
Day 1
Cycle 6
Day 1
End of
Treatment
Follow-up
Q1
Follow-up
Day 181
N=29
N=24
N=12
N=8
N=73
CR
PR
SD
PD/NE
All
N=32
N=27
N=10
N=6
N=75
N=33
N=24
N=8
N=5
N=70
N=32
N=23
N=8
N=4
N=67
N=29
N=22
N=7
N=3
N=61
N=24
N=22
N=7
N=2
N=55
N=33
N=27
N=12
N=4
N=76
N=29
N=16
N=6
N=51
N=29
N=23
N=4
N=56
N=28
N=24
N=12
N=8
N=72
CR
PR
SD
PD/NE
All
N=32
N=27
N=10
N=6
N=75
N=33
N=24
N=8
N=5
N=70
N=32
N=23
N=8
N=4
N=67
N=29
N=22
N=7
N=3
N=61
N=24
N=21
N=7
N=2
N=54
N=33
N=27
N=12
N=4
N=76
N=29
N=16
N=6
N=51
N=29
N=23
N=4
N=56
AllPD/NESDPRCR
Cycle 1
Day 1
Time
Cycle 2
Day 1
Cycle 3
Day 1
Cycle 4
Day 1
Cycle 5
Day 1
Cycle 6
Day 1
End of
Treatment
Follow-up
Q1
Follow-up
Day 181
N
eu
tr
op
hi
l c
ou
nt
 (
10
3 /
m
L)
0
1
2
3
4
N=29
N=24
N=12
N=8
N=73
CR
PR
SD
PD/NE
All
N=32
N=27
N=10
N=6
N=75
N=33
N=24
N=8
N=5
N=70
N=32
N=23
N=8
N=4
N=67
N=29
N=22
N=7
N=3
N=61
N=24
N=22
N=7
N=2
N=55
N=33
N=27
N=12
N=4
N=76
N=29
N=16
N=6
N=51
N=29
N=23
N=4
N=56
AllPD/NESDPRCR
Cycle 1
Day 1
Time
Cycle 2
Day 1
Cycle 3
Day 1
Cycle 4
Day 1
Cycle 5
Day 1
Cycle 6
Day 1
End of
Treatment
Follow-up
Q1
Follow-up
Day 181
50
100
150
200
Pl
at
el
et
 c
ou
nt
 (
10
3 /
m
L)
N=30
N=25
N=11
N=8
N=74
CR
PR
SD
PD/NE
All
N=30
N=22
N=7
N=1
N=60
N=22
N=12
N=1
N=35
AllPD/NESDPRCR
Screening End of
Treatment
Follow-up
Day 181
H&E
Pr
et
re
at
m
en
t
Po
st
tr
ea
tm
en
t
0
20
40
60
80
100
H
&
E 
pe
rc
en
ta
ge
CR
PR
SD
PD/NE
All
AllPD/NESDPRCR
Screening End of
Treatment
Follow-up
Day 181
17
7.5
10.0
12.5
15.0
17.5
20.0
Sp
le
en
 s
iz
e 
(c
m
)
N=32
N=25
N=10
N=7
N=74
N=30
N=25
N=10
N=3
N=68
N=29
N=19
N=3
N=51
0
40 μg/kg N=33 N=24 N=9 N=7 N=6 N=5 N=2
0.0
0.2
0.4
Ka
pl
an
-M
ei
er
 r
es
po
ns
e 
ra
te
0.6
0.8
1.0
6 12 18 24
Time (months)
40 μg/kg
No. of events
Median (months) (95% CI)
Landmark rate at 6 months
Landmark rate at 12 months
N=33
2
NR (NE, NE)
92.4% (73.0, 98.1)
92.4% (73.0, 98.1)
30 36 42
a b
c
d
Fig. 1 Evaluation of primary end point (blinded independent central
review). a Hemoglobin (top), neutrophil counts (middle), and platelet
counts (bottom) over time, as a function of best objective response.
Median and interquartile range are shown at each displayed time point
and the threshold for hematologic remission is indicated as a dotted
line. b HCL involvement in bone marrow, assessed by hematoxylin
and eosin stain, as a function of best objective response; median and
interquartile range are shown (top), and as representative pretreatment
and posttreatment images (×100) of a patient who obtained a minimal
residual disease-negative complete response (bottom). Yellow arrows
indicate hairy cells. c Spleen size by imaging, as a function of best
objective response. Median and interquartile range are shown. Sple-
nectomy patients (n= 5) not included. d Kaplan–Meier plot of dura-
tion of hematologic remission from complete response
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patients (75.0%) received prior rituximab and 14 patients
(17.5%) received prior BRAF-inhibitor (Table S1 in Sup-
plementary Appendix).
Efﬁcacy
Median hemoglobin, neutrophil count, and platelet count
improved rapidly during treatment (Fig. 1a); 80% of
patients (64/80) achieved hematologic remission in about
one month (median 1.1 months, 95% CI, 1.0 to 1.2). At a
median follow-up of 16.7 months [2.1 to 48.8]), the durable
complete response rate was 30% (24/80 patients; 95% CI,
20.3 to 41.3), and the objective response rate was 75% (60/
80 patients, 95% CI, 64.1 to 84.0; Table 2) based on blinded
independent central review. The complete response rate was
41% (33/80 patients; 95% CI, 30.4 to 52.8). Thirty-three
patients achieved complete response, including elimination
of leukemic cells in bone marrow by morphologic assess-
ment; signiﬁcant (>90%) reductions in bone marrow
involvement were also observed in 29.6% of patients
achieving partial response (8/27; Fig. 1b). Average spleen
size decreased during treatment, and among patients with
baseline splenomegaly (17 cm or larger), 6 (42.9%)
resolved to 14 cm or smaller (Fig. 1c).
Most (28/33) complete responses were achieved at the
end of treatment disease assessment; ﬁve patients achieved
complete response at disease assessment six months after
the end of treatment. The median duration of hematologic
remission from complete response (Fig. 1d), median dura-
tion of complete response, and median progression-free
survival were not reached. Six patients relapsed from
complete response as of the data cut-off; four had asymp-
tomatic relapse with only reappearance of hairy cells in the
bone marrow with normal hematological counts and
two had loss of hematologic remission. Among complete
responders, 27 (85%) patients achieved minimal
residual disease negativity as assessed by immunohis-
tochemistry (Table 2 and Fig. 2). The median duration of
complete response for minimal residual disease-positive
patients was 5.9 months and was not reached for minimal
residual disease-negative patients (Fig. 2b). Subgroup ana-
lyses are presented in Figure S2 in the Supplementary
Appendix.
Safety
The most common adverse events were peripheral edema
(38.8%), nausea (35.0%), and fatigue (33.8%) (Table 3); the
most common treatment-related adverse events were nausea
(27.5%), peripheral edema (26.3%), headache (21.3%), and
pyrexia (20.0%). The most common treatment-related grade
3/4 adverse events were decreased lymphocyte count
(7.5%) and hemolytic uremia syndrome (5.0%). Grade 3 or
4 infections occurred in 13 (16.3%) patients, with infections
in 2 patients (2.5%) reported as treatment related. Serious
adverse events in at least 5% of patients were hemolytic
uremic syndrome (7.5%), pyrexia (6.3%), and capillary leak
syndrome (5.0%). Three deaths occurred on study due to
pneumonia, septic shock, and sepsis syndrome and under-
lying HCL; none were considered treatment related. The
most common treatment-related adverse events leading to
permanent discontinuation were hemolytic uremic syn-
drome (n= 4), capillary leak syndrome (n= 2), and blood
creatinine increased (n= 2; associated with hemolytic ure-
mic syndrome). All hemolytic uremic syndrome and capil-
lary leak syndrome events were reversible. Details
Table 2 Disease response and
minimal residual disease status
by immunohistochemistry
Parameter Value (N= 80)
Blinded independent central
review
Investigator assessment
Durable complete response (primary end
point), n (%)a
24 (30.0) 38 (47.5)
95% conﬁdence interval 20.3, 41.3 36.2, 59.0
Best overall responsea
Complete response, n (%) 33 (41.3) 41 (51.3)
95% conﬁdence interval 30.4, 52.8 39.8, 62.6
Complete response, minimal residual
disease negative, n (%)
27 (33.8) 26 (32.5)
95% conﬁdence interval 23.6, 45.2 22.4, 43.9
Partial response, n (%) 27 (33.8) 27 (33.8)
Objective response rate (complete or partial
response), n (%)a
60 (75.0) 63 (78.8)
95% conﬁdence interval 64.1, 84.0 68.2, 87.1
aTwo-sided conﬁdence interval was calculated using the exact probability method based on the binomial
distribution
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regarding hemolytic uremic syndrome/capillary leak syn-
drome cases are presented in the Supplementary Appendix.
Key laboratory ﬁndings are presented in Table S2. The
median key immunoglobulin (IgA, IgG, and IgM) levels
remained unchanged after treatment. Median CD4 T cell
counts were stable or increased following a transient
decrease on day eight.
Pharmacokinetics, immunogenicity, and
pharmacodynamics
Moxetumomab pasudotox pharmacokinetics were char-
acterized by rapid plasma concentration decline following
intravenous administration (Table S3 and Figure S3A in
Supplementary Appendix). Exposure was higher after
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Fig. 2 Assessment of minimal
residual disease by
immunohistochemistry (blinded
independent central review).
a Representative
immunohistochemistry images
from pretreatment and
posttreatment bone marrow
biopsy specimens of the same
patient shown in Fig. 1b: CD20
(left) and PAX5/TRAP (right).
b Kaplan–Meier plot of duration
of complete response, by
minimal residual disease status
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subsequent doses versus the ﬁrst dose, likely related to
treatment-mediated reduction of the CD22 sink (Figure S3B
in Supplementary Appendix). Anti-drug antibodies were
detected at baseline in 45/76 evaluable patients (59.2%).
The frequency of neutralizing antibodies and anti-drug
antibody titer increased with repeated cycles of treatment;
reduced drug exposure was observed in patients with high-
titer (>10 000) anti-drug antibodies (Figures S3C and S3D
in Supplementary Appendix). Median peripheral blood
CD19 B cell counts (including normal B cells and hairy
cells) were reduced by 90% on day eight, remained low
through the end of treatment, and, for patients with partial
or complete response, returned to approximately normal
levels at six months posttreatment (Figure S3E in Supple-
mentary Appendix).
Discussion
To date, this pivotal study is the largest prospective study in
third-line or beyond relapsed/refractory HCL; it is also the
ﬁrst study using durable complete response (deﬁned as
complete response assessed by blinded independent central
review with maintenance of hematologic remission for more
than 180 days) as the primary end point. Patients were
heavily pretreated; 50% received three or more prior cour-
ses of purine nucleoside analogs and 75% received prior
rituximab. The blinded independent central review-assessed
complete response rate of 41% represents a substantial
improvement over historical controls, and the durable
complete response rate of 30% met the primary end point.
In HCL, immunohistochemistry staining of a high-quality
bone marrow biopsy may provide more consistent minimal
residual disease evaluation than ﬂow cytometry of bone
marrow aspirates, which depend on a consistent cellular
yield [8]. Published data suggest that the extent of minimal
residual disease remaining after therapy in HCL is impor-
tant in predicting long-term outcome [23, 24]. Retrospective
analysis of the phase 1 study of moxetumomab pasudotox
in a similar patient population of relapsed/refractory HCL
showed that patients who were minimal residual disease-
negative by immunohistochemistry had extended duration
of response (82.7 versus 54.7 months). This result sup-
ported the possible predictive value of immunochemistry-
based minimal residual disease for long-term outcome. In
this study, a majority of patients (27/33) who achieved
complete response also achieved negative minimal residual
disease by immunohistochemistry. While long-term follow-
up is ongoing, the fact that the median duration of complete
response was reached for minimal residual disease-positive
patients (5.9 months; with limitation of small patient num-
bers) but has not for minimal residual disease-negative
patients indicates that long-term outcome may be improved
by clearing minimal residual disease.
Consistent with prior studies of moxetumomab pasudo-
tox and its predecessor molecule BL22 (CAT-3888) [25,
26], in this pivotal study, response rates were higher in
patients who did not have splenomegaly or splenectomy
(which was associated with high disease burden in the bone
marrow; 4 of the 5 patients had 100% involvement at
baseline). Three patients with HCL variant were enrolled;
all had high disease burden (all had splenomegaly >18 cm
and two had lymphocytosis >20/nL) and did not achieve
complete response. According to these observations, it may
be advisable to initiate moxetumomab pasudotox treatment
earlier in relapse when possible in patients with very high
disease burden; further studies would be required to deter-
mine whether a more intensive treatment regimen might
improve response rates in these patients.
Table 3 Summary of adverse eventsa
Adverse event All grades Grades 3/4
Patients, n (%)
Edema peripheral 31 (38.8%) 0
Nausea 28 (35.0%) 2 (2.5%)
Fatigue 27 (33.8%) 0
Headache 26 (32.5%) 0
Pyrexia 25 (31.3%) 1 (1.3%)
Hypocalcaemia 19 (23.8%) 0
Hypophosphatemia 19 (23.8%) 8 (10.0%)
Constipation 18 (22.5%) 0
Anemia 17 (21.3%) 8 (10.0%)
Diarrhea 17 (21.3%) 0
Alanine aminotransferase increased 17 (21.3%) 1 (1.3%)
Lymphocyte count decreased 16 (20.0%) 16 (20.0%)
Hypoalbuminemia 16 (20.0%) 0
Hypokalemia 13 (16.3%) 2 (2.5%)
Hypertension 12 (15.0%) 6 (7.5%)
Platelet count decreased 9 (11.3%) 5 (6.3%)
Hyponatremia 9 (11.3%) 2 (2.5%)
White blood cell count decreased 8 (10.0%) 7 (8.8%)
Capillary leak syndrome 7 (8.8%) 2 (2.5%)
Upper respiratory infection 7 (8.8%) 2 (2.5%)
Hemolytic uremic syndrome 6 (7.5%) 4 (5.0%)
Neutrophil count decreased 6 (7.5%) 5 (6.3%)
Febrile neutropenia 5 (6.3%) 4 (5.0%)
Neutropenia 4 (5.0%) 4 (5.0%)
Hypoxia 4 (5.0%) 2 (2.5%)
Lung infection 3 (3.8%) 2 (2.5%)
Acute kidney injury 3 (3.8%) 2 (2.5%)
Erysipelas 2 (2.5%) 2 (2.5%)
aAdverse events of any grade with an incidence of at least 20%, as well
as events of grade 3 or grade 4 with an incidence of at least 2.5%
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Substantial clinical activity was observed despite a high
rate of immunogenicity; ~75% of patients had detectable
neutralizing antibodies at the end of treatment, regardless of
response status. Patients who achieved complete or partial
response typically maintained antibody titers below 10,000,
and therefore maintained drug exposure for more treatment
cycles than patients with stable or progressive disease,
suggesting that approaches to reduce the immunogenicity of
moxetumomab pasudotox might further improve response.
Hemolytic uremia syndrome and capillary leak syndrome
were known toxicities and observed in the moxetumomab
pasudotox phase 1 study and in studies of BL22 [25, 27]. In
the current study, these events (observed in 10 patients
[12.5%]) were typically managed with close monitoring of
vital signs and laboratory values (including blood pressure,
body weight, blood creatinine, and schistocytes in peripheral
blood smear) and supportive medical care (including adequate
hydration), with intensive care without plasma exchange and
treatment discontinuation for severe cases. Although the exact
mechanisms are not well understood, our experience suggests
that incidence and severity of hemolytic uremia syndrome and
capillary leak syndrome may be reduced by ensuring adequate
oral hydration during the ﬁrst week of each cycle and proper
(not excessive) intravenous ﬂuid supplementation on the day
of infusion. Dexamethasone may be considered in patients
experiencing nausea or fever, to maintain oral hydration for
adequate renal perfusion. Worsening renal function was
observed in isolation and in association with hemolytic ure-
mia syndrome; based on these ﬁndings, close monitoring of
renal function is recommended during treatment.The pivotal
study data demonstrate that moxetumomab pasudotox pro-
vides a deep and durable response with ability to eradicate
minimal residual disease in a substantial fraction of patients
with relapsed/refractory HCL who have exhausted available
therapies, and has a favorable safety proﬁle compared to other
available agents. A high percentage of patients were able to
receive the full treatment course, and the most important risks,
hemolytic uremia syndrome, and capillary leak syndrome,
although relatively infrequent, were manageable and rever-
sible with close monitoring and best supportive care. Mox-
etumomab pasudotox treatment results in substantially less
bone marrow suppression than purine nucleoside analogs,
without exacerbating baseline infections. In conclusion,
moxetumomab pasudotox offers a clinically meaningful
treatment for patients with relapsed/refractory HCL.
Data availability
The data sets generated and/or analyzed during the current
study are available from the corresponding author upon
reasonable request.
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